US medical device and pharmaceutical company Speranza Therapeutics on Wednesday announced a strategic partnership with Canada-based Sunshine Labs, which specialises in harm reduction, safer supply, and science-backed therapeutic innovation.

This collaboration is claimed to be a significant milestone in expanding access to clinically effective medical devices, pharmaceuticals, and harm reduction tools across the United States and key international markets.

Sunshine Labs, operating under Health Canada's Controlled Drugs and Substances Act, is involved in transforming how controlled substances are regulated, studied, and administered. Through its wholly owned subsidiary, Oryx Biomed, Sunshine Labs delivers pharmaceutical-grade treatments and research-ready substances to global markets including the United Kingdom, Australia, and European Union member states.

Together, Speranza Therapeutics and Sunshine Labs will work to equip providers, clinicians, and researchers with innovative solutions that address addiction, mental health challenges, and overdose prevention. Key areas of collaboration include: medical devices (including Speranza's ST Genesis Neurostimulation Device for Detox, and Sunshine Labs' advanced Naloxone delivery system, designed to support rapid response in overdose scenarios); psychedelics for therapeutic use (supporting ongoing clinical trials and research focused on PTSD, substance use disorder, and treatment-resistant mental health conditions); compounding pharmacy services (delivering personalised, high-quality treatment formulations for complex psychiatric and behavioural health needs); and pharmaceutical-grade treatments (manufactured to the highest cGMP and euGMP standards, ensuring quality, consistency, and compliance across global markets).